Acura Pharmaceuticals (ACUR): Price and Financial Metrics


Acura Pharmaceuticals (ACUR): $0.52

0.00 (0.19%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ACUR Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for ACUR is 16.63 -- better than 98.48% of US stocks.
  • With a year-over-year growth in debt of -94.83%, Acura Pharmaceuticals Inc's debt growth rate surpasses merely 2.08% of about US stocks.
  • As for revenue growth, note that ACUR's revenue has grown -44.87% over the past 12 months; that beats the revenue growth of merely 4.45% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Acura Pharmaceuticals Inc are TCCO, SONM, QUAD, KODK, and RRGB.
  • ACUR's SEC filings can be seen here. And to visit Acura Pharmaceuticals Inc's official web site, go to www.acurapharm.com.

ACUR Valuation Summary

  • In comparison to the median Healthcare stock, ACUR's EV/EBIT ratio is 216.04% lower, now standing at -34.
  • ACUR's price/sales ratio has moved up 14 over the prior 243 months.
  • ACUR's price/sales ratio has moved up 14 over the prior 243 months.

Below are key valuation metrics over time for ACUR.

Stock Date P/S P/B P/E EV/EBIT
ACUR 2021-08-31 16.1 100.5 -24.5 -34.0
ACUR 2021-08-30 15.0 93.7 -22.8 -31.7
ACUR 2021-08-27 16.1 100.5 -24.5 -34.0
ACUR 2021-08-26 14.7 91.9 -22.4 -31.1
ACUR 2021-08-25 13.7 85.3 -20.8 -28.9
ACUR 2021-08-24 15.0 93.7 -22.8 -31.7

ACUR Growth Metrics

  • The 3 year price growth rate now stands at -90.57%.
  • Its 4 year net income to common stockholders growth rate is now at 62.74%.
  • Its 3 year cash and equivalents growth rate is now at -97.11%.
Over the past 49 months, ACUR's revenue has gone down $4,407,000.

The table below shows ACUR's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 2.385 -1.132 -1.567
2021-03-31 3.123 -1.379 -0.872
2020-12-31 3.57 -0.719 -1.208
2020-09-30 4.072 -0.117 -0.81
2020-06-30 4.986 1.028 0.068
2020-03-31 3.681 0.128 -3.581

ACUR Stock Price Chart Interactive Chart >

Price chart for ACUR

ACUR Price/Volume Stats

Current price $0.52 52-week high $0.75
Prev. close $0.52 52-week low $0.15
Day low $0.52 Volume 1,894
Day high $0.55 Avg. volume 12,569
50-day MA $0.54 Dividend yield N/A
200-day MA $0.48 Market Cap 33.91M

Acura Pharmaceuticals (ACUR) Company Bio


Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. The company has six additional opioid products in various stages of formulation development. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc.; and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was founded in 1935 and is based in Palatine, Illinois.


ACUR Latest News Stream


Event/Time News Detail
Loading, please wait...

ACUR Latest Social Stream


Loading social stream, please wait...

View Full ACUR Social Stream

Latest ACUR News From Around the Web

Below are the latest news stories about Acura Pharmaceuticals Inc that investors may wish to consider to help them evaluate ACUR as an investment opportunity.

Acura Pharmaceuticals Announces Third Quarter 2021 Financial Results

PALATINE, Ill., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR), an innovative drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications, announced today financial results for the three and nine months ended September 30, 2021.

Intrado Digital Media | November 15, 2021

Acura Pharmaceuticals Announces Third Quarter 2021 Financial Results

PALATINE, Ill., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR), an innovative drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications, announced today financial results for the three and nine months ended September 30, 2021. The Company reported revenues of $270 thousand, an operating loss of $531 thousand and a net loss of $262 thousand or $0.00 per diluted share for th

Yahoo | November 15, 2021

Acura Pharmaceuticals (OTCMKTS:ACUR) Stock Crosses Above 200-Day Moving Average of $0.52

Acura Pharmaceuticals, Inc. (OTCMKTS:ACUR)s share price passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.52 and traded as high as $0.56. Acura Pharmaceuticals shares last traded at $0.56, with a volume of 12,403 shares changing hands. The stock has a market capitalization of $12.38 []

Dakota Financial News | November 10, 2021

Acura Pharmaceuticals Announces Second Quarter 2021 Financial Results

PALATINE, Ill., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR), an innovative drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications, announced today financial results for the three and six months ended June 30, 2021.

Intrado Digital Media | August 16, 2021

Acura Pharmaceuticals and AD Pharma Amend License to LIMITx LTX-03

Amendment Extends NDA Acceptance Date Amendment Extends NDA Acceptance Date

Intrado Digital Media | July 26, 2021

Read More 'ACUR' Stories Here

ACUR Price Returns

1-mo -5.45%
3-mo -11.86%
6-mo 42.47%
1-year 108.00%
3-year 136.36%
5-year -43.48%
YTD 147.62%
2020 -8.70%
2019 100.17%
2018 -71.55%
2017 -47.55%
2016 -69.20%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7493 seconds.